In our February issue of Pharmaceutical Executive
FEATURES
Cover Feature
Jay Galeota: A Better Way to Pharma
Lisa Henderson
Veteran pharma leader Jay Galeota, CEO of Inheris Biopharma, shares learnings and perspectives from an off-the-beaten-path career rise.
Download the digital issue
|
ADVERTISEMENT
Break Free from Forecast Inaccuracy: How Machine Learning Can Drive Better Quality Commercial Forecasting
Thursday, February 20, 2020 at 11am EST | 8am PST | 4pm GMT | 5pm CET
Register Now |
Reaching the Physician in 2020
Engaging the New HCP in the Digital World
Lisa Henderson
Amid the growth but still-cautious embrace of social media and other digital marketing channels, appealing to the younger physician requires a nuanced approach—mixing proven expertise with fresh ideas.
Download the digital issue |
ADVERTISEMENT
Market Pricing Dynamics for the Machine Learning Age
Are You Getting the Insights You Need?
Thursday, March 26, 2019 at 11am EDT |10am CDT |4pm BST |5pm CEST
Register Now |
Reaching the Physician in 2020
Surfacing Insights: AI and the HCP
Julian Upton
Exploring the advent of data analytics and pharma marketing automation in guiding targeted messaging and brand engagement.
Download the digital issue |
ADVERTISEMENT
The 5 Safes of Risk-Based Anonymization
Wednesday, February 26, 2020 at 10am EST | 9am CST | 3pm GMT | 4pm CET
Register Now |
Reaching the Physician in 2020
Improving the Link from Lab to Physician
Elaine Quilici
How current barriers along the roadway between biomarker testing and drug prescribing can affect decision-making for precision medicines.
Download the digital issue |
ADVERTISEMENT
Virtual, Decentralized, Site-less Trials… What Does it All Mean?
Thursday, March 12, 2020 at 11am EDT | 8am PDT | 3pm GMT | 4pm CET
Register Now |
ALSO IN THIS ISSUE
Becoming a Pharma Industry Leader
Lisa Henderson
With the nomination period for our latest Emerging Pharma Leaders selections in full swing, it's a good reminder that the industry's future path ultimately depends on its leaders, emerging and otherwise …Read more
The Risks and Rewards of Expedited Review
Jill Wechsler
Weighing new strategies to accelerate biomedical product development …Read more
Unlocking the Black Box of Pharma Pricing in Europe
Reflector
New OECD study doesn’t shed much light on the effectiveness of managed entry agreements for drug access …Read more
|
ADVERTISEMENT
The Current and Future Impact of Artificial Intelligence (AI) on Pharmacovigilance
Tuesday, February 11, 2020 at 11am EST| 8am PST| 4pm GMT| 5pm CET
Register Now |
